A Nationwide Study on the Incidence of Breast Cancer in Korean Women with Osteoporosis Receiving Raloxifene Treatment

다국어 초록 (Multilingual Abstract)

Purpose: Raloxifene is a selective estrogen receptor modulator (SERM), and raloxifene treatment for osteoporosis is reimbursable under the Korean National Health Insurance. Evidence suggests that SERMs use reduces the risk of breast cancer in Asian population. Herein, we retrospectively investigated the protective effect of raloxifene on breast cancer rates in Korean population.
Methods: Using the Health Insurance Review and Assessment Service database, we selected women with osteoporosis aged 50 years and above. Patients treated for at least 2 years with raloxifene were assigned to the user group, whereas the remaining patients were assigned to the non-user group. The effect on breast cancer risk was assessed using the Cox proportional-hazards model with a time-dependent covariate to adjust for immortal time bias.
Results: A total of 322,870 women who were registered between 2010 and 2011 were included. The user group comprised 0.7% (n = 2,307) of the total population. The mean age was 65.7 ± 8.0 years and 67.2 ± 8.6 years in the user and non-user groups, respectively (p < 0.001). There was no difference in the previous use of estrogen replacement between the 2 groups (p = 0.087). The incidence of breast cancer per 1,000 person-years was 0.49 (n = 8) and 0.68 (n = 1,714) in the user and non-user groups, respectively (hazard ratio [HR], 0.63, 95% confidence interval [CI], 0.32–1.27). HR decreased with increase in the treatment duration, but this change was not statistically significant (HR, 1.00, 95% CI, 0.32–3.11 in 2–3 years; HR, 0.63, 95% CI, 0.20–1.94 in 3–4 years; and HR, 0.41, 95% CI, 0.10–1.65 in 4–5 years).
Conclusion: Long-term treatment with raloxifene in women with osteoporosis was not significantly associated with a reduction in breast cancer rates. However, further investigation is required for a conclusive proof.

참고문헌 (Reference)

1 Hill K, "The demography of menopause" 23 : 113-127, 1996

2 Aihara T, "The Japanese Breast Cancer Society clinical practice guideline for systemic treatment of breast cancer, 2015 edition" 23 : 329-342, 2016

3 Fisher B, "Tamoxifen for the prevention of breast cancer : current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study" 97 : 1652-1662, 2005

4 Grady D, "Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk" 100 : 854-861, 2008

5 National Comprehensive Cancer Network (NCCN), "NCCN clinical practice guidelines in oncology. Breast cancer. Plymouth Meeting"

6 Kreienberg R, "Interdisciplinary GoR level III guidelines for the diagnosis, therapy and follow-up care of breast cancer: short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012" 73 : 556-583, 2013

7 Smith SG, "Factors affecting uptake and adherence to breast cancer chemoprevention : a systematic review and meta-analysis" 27 : 575-590, 2016

8 Cauley JA, "Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer" 130 : 270-277, 1999

9 Vogel VG, "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : the NSABP Study of Tamoxifen and Raloxifene(STAR)P-2 trial" 295 : 2727-2741, 2006

10 Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women" 355 : 125-137, 2006

11 Martino S, "Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene" 96 : 1751-1761, 2004

12 Cauley JA, "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation" 65 : 125-134, 2001

13 Kim J, "Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis : from a national health insurance claims database" 10 : e0127970-, 2015

14 Lin TC, "Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women" 98 : 4717-4726, 2013

15 Flanagan MR, "Chemoprevention uptake for breast cancer risk reduction varies by risk factor" 26 : 2127-2135, 2019

16 Foster SA, "Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates" 8 : 24-, 2008

17 LaCroix AZ, "Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women" 102 : 1706-1715, 2010

18 Powles TJ, "Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene" 134 : 299-306, 2012

19 Cauley JA, "Bone mineral density and risk of breast cancer in older women : the study of osteoporotic fractures" 276 : 1404-1408, 1996

20 Zhang Y, "Bone mass and the risk of breast cancer among postmenopausal women" 336 : 611-617, 1997

21 Visvanathan K, "American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction" 27 : 3235-3258, 2009

22 Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples" 36 : e2014008-, 2014